Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication

Panda, Kingshuk; Alagarasu, Kalichamy; Parashar, Deepti

doi:10.3390/molecules26040956

Cited by 8 publications

(5 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exogenous delivery involves directly introducing ribozyme into cells through a delivery vehicle, whereas endogenous delivery involves expressing ribozyme within cells using plasmids or viral vectors [ 71 ]. Once inside the cells, the ribozymes can bind to and cleave the viral RNA, preventing replication of the virus [ 72 ]. The ribozyme ribonuclease P (RNase P) is a unique RNase as it is an RNA catalyst similar to a protein enzyme [ 73 ].…”

Section: Possible Alternative Strategies To Combat Hcmv Infectionmentioning

confidence: 99%

“…Aptamers are single-stranded DNA, RNA or peptide molecules that can be engineered to bind to the specific target molecule [ 86 ]. Aptamers can be designed to bind to and inhibit critical components of the virus, such as viral protein or RNA [ 72 ]. Aptamers have previously been used to target proteins required for virus entry into the host cells, such as cellular receptors and viral envelope proteins [ 87 , 88 ].…”

Section: Possible Alternative Strategies To Combat Hcmv Infectionmentioning

confidence: 99%

See 1 more Smart Citation

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

Panda

Parashar

Viswanathan

2023

Viruses

Self Cite

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) remains an essential global concern due to its distinct life cycle, mutations and latency. As HCMV is a herpesvirus, it establishes a lifelong persistence in the host through a chronic state of infection. Immunocompromised individuals are at risk of significant morbidity and mortality from the virus. Until now, no effective vaccine has been developed to combat HCMV infection. Only a few antivirals targeting the different stages of the virus lifecycle and viral enzymes are licensed to manage the infection. Therefore, there is an urgent need to find alternate strategies to combat the infection and manage drug resistance. This review will provide an insight into the clinical and preclinical antiviral approaches, including HCMV antiviral drugs and nucleic acid-based therapeutics.

show abstract

Section: Possible Alternative Strategies To Combat Hcmv Infectionmentioning

confidence: 99%

Section: Possible Alternative Strategies To Combat Hcmv Infectionmentioning

confidence: 99%

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

Panda

Parashar

Viswanathan

2023

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, AS-ODN directly acts on viral genomic RNA or transcripts and can be rationally designed for the treatment of human immunodeficiency virus (HIV), hepatitis B and C viruses (HBV and HCV), herpes viruses or any new virus ( Panda et al, 2021 ). Fomivirsen (Vitravene), an anti-cytomegalovirus (CMV) agent, is the first AS-ODN to be approved by the FDA as an antiviral therapy.…”

Section: Therapeutic Applications Of Inhibitory Odns In Immune-mediat...mentioning

confidence: 99%

Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases

Wang

Chen

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Inhibitory oligodeoxynucleotides (ODNs) are short single-stranded DNA, which capable of folding into complex structures, enabling them to bind to a large variety of targets. With appropriate modifications, the inhibitory oligodeoxynucleotides exhibited many features of long half-life time, simple production, low toxicity and immunogenicity. In recent years, inhibitory oligodeoxynucleotides have received considerable attention for their potential therapeutic applications in immune-mediated inflammatory diseases (IMIDs). Inhibitory oligodeoxynucleotides could be divided into three categories according to its mechanisms and targets, including antisense ODNs (AS-ODNs), DNA aptamers and immunosuppressive ODNs (iSup ODNs). As a synthetic tool with immunomodulatory activity, it can target RNAs or proteins in a specific way, resulting in the reduction, increase or recovery of protein expression, and then regulate the state of immune activation. More importantly, inhibitory oligodeoxynucleotides have been used to treat immune-mediated inflammatory diseases, including inflammatory disorders and autoimmune diseases. Several inhibitory oligodeoxynucleotide drugs have been developed and approved on the market already. These drugs vary in their chemical structures, action mechanisms and cellular targets, but all of them could be capable of inhibiting excessive inflammatory responses. This review summarized their chemical modifications, action mechanisms and applications of the three kinds of inhibitory oligodeoxynucleotidesin the precise treatment of immune-mediated inflammatory diseases.

show abstract

“…Theoretically, as previously mentioned, siRNA modalities can be designed and targeted to silence any viral gene of interest, which makes them efficient tools for a broad range of antiviral applications [ 53 ]. Despite the promising therapeutic benefits of siRNAs, several obstacles, such as the instability of siRNAs, delivery problems, off-target effects, immunological responses, and development of drug resistance, have hindered their application (Table 1 ).…”

Section: Challenges Of Sirna Treatments For Viral Infectionsmentioning

confidence: 99%

Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges

Kang,

Ga,

Kim

et al. 2023

J Biomed Sci

View full text Add to dashboard Cite

RNA has emerged as a revolutionary and important tool in the battle against emerging infectious diseases, with roles extending beyond its applications in vaccines, in which it is used in the response to the COVID-19 pandemic. Since their development in the 1990s, RNA interference (RNAi) therapeutics have demonstrated potential in reducing the expression of disease-associated genes. Nucleic acid‐based therapeutics, including RNAi therapies, that degrade viral genomes and rapidly adapt to viral mutations, have emerged as alternative treatments. RNAi is a robust technique frequently employed to selectively suppress gene expression in a sequence-specific manner. The swift adaptability of nucleic acid‐based therapeutics such as RNAi therapies endows them with a significant advantage over other antiviral medications. For example, small interfering RNAs (siRNAs) are produced on the basis of sequence complementarity to target and degrade viral RNA, a novel approach to combat viral infections. The precision of siRNAs in targeting and degrading viral RNA has led to the development of siRNA-based treatments for diverse diseases. However, despite the promising therapeutic benefits of siRNAs, several problems, including impaired long-term protein expression, siRNA instability, off-target effects, immunological responses, and drug resistance, have been considerable obstacles to the use of siRNA-based antiviral therapies. This review provides an encompassing summary of the siRNA-based therapeutic approaches against viruses while also addressing the obstacles that need to be overcome for their effective application. Furthermore, we present potential solutions to mitigate major challenges.

show abstract

Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication

Cited by 8 publications

References 119 publications

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases

Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges

Contact Info

Product

Resources

About